Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

(2016) V.J. Ludbrook et al.   BRITISH JOURNAL OF DERMATOLOGY

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184

(2015) R F van Vollenhoven et al.   LUPUS

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia

(2014) J. Grisouard et al.   HAEMATOLOGICA

Systemic lupus erythematosus activity and beta two microglobulin levels

(2014) Thelma Larocca Skare et al.   Sao Paulo Medical Journal

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors

(2013) S. J. Sohn et al.   JOURNAL OF IMMUNOLOGY

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The many faces of Janus kinase

(2011) Matthew M. Seavey et al.   BIOCHEMICAL PHARMACOLOGY

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

(2011) Claude Haan et al.   CHEMISTRY & BIOLOGY

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

(2010) Richard J. Riese et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Multiorgan Antiviral T Cell Response

(2010) D. Picard et al.   Science Translational Medicine

Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus

(2009) Yihong Yao et al.   ARTHRITIS AND RHEUMATISM

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Type I Interferon: Potential Therapeutic Target for Psoriasis?

(2008) Yihong Yao et al.   PLoS One